GlassScriptPhysician profile
Reginald Casilang
NPI 1780784488
$11,844.39
in general payments reported to CMS, 2019-2025
30 companies · $2,862 in 2025
The $2,862 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,461 · 2022: $2,530 · 2023: $1,851 · 2024: $2,141 · 2025: $2,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,853.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,109.71 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $1,729.06 | 2021-2025 | Aristada, Lybalvi |
| Abbvie INC. | $1,463.46 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $949.08 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $751.30 | 2021-2025 | Caplyta |
| Noven Therapeutics, LLC | $736.35 | 2021-2025 | Xelstrym, Secuado |
| Otsuka America Pharmaceutical, INC. | $672.40 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $397.56 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $394.47 | 2021-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $362.43 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $308.30 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $275.83 | 2022-2024 | |
| Axsome Therapeutics, INC. | $255.94 | 2023-2025 | Auvelity |
| Indivior INC. | $238.06 | 2022-2025 | Perseris, Sublocade |
| Lundbeck LLC | $217.46 | 2023-2025 | Rexulti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $162.43 | 2022-2024 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $143.08 | 2023-2024 | Quviviq |
| Adlon Therapeutics L.P. | $131.31 | 2021 | |
| Corium, LLC | $130.10 | 2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $111.35 | 2022-2025 | Qelbree, Qelbree |
| Noven Pharmaceuticals, INC. | $105.39 | 2021-2024 | Xelstrym |
| Collegium Pharmaceutical, INC. | $45.28 | 2025 | Jornay Pm |
| Tris Pharma INC | $32.10 | 2024 | Dyanavel Xr |
| Allergan, INC. | $27.51 | 2021 | |
| Avanir Pharmaceuticals, INC. | $23.62 | 2021 | |
| Neos Therapeutics, LP | $19.92 | 2025 | Adzenys Xr-Odt |
| Eisai INC. | $17.74 | 2021 | |
| Biogen, INC. | $15.10 | 2024 | |
| Sumitomo Pharma America, INC. | $10.25 | 2023 | Latuda |
| Brainsway USA INC | $7.80 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reginald Casilang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.